Description du projet
Simplifier le diagnostic par la nanotechnologie
Les essais diagnostiques sont la pierre angulaire des décisions en matière de soins de santé prises aujourd’hui et ils sont essentiels pour mettre en place un traitement efficace. Les outils de diagnostic doivent montrer une capacité d’analyse haut débit ainsi qu’une qualité élevée de données et consommer de petits volumes d’échantillon. La nanotechnologie permet de faire avancer le diagnostic moléculaire sur le lieu d’intervention. Afin de répondre à ce besoin, le projet Nano4, financé par l’UE, a développé NANO4, une nanotechnologie de diagnostic rapide qui utilise des nanosondes pour détecter les molécules d’ADN et d’ARN. Le résultat est visible grâce à un changement de couleurs, ce qui rend le dispositif extrêmement simple d’utilisation et facilite la prise de décision rapide. L’idée initiale consiste à mettre en œuvre NANO4 pour le diagnostic de la tuberculose et de la leucémie, qui représentent des problèmes médicaux internationaux.
Objectif
There is a need for cost-effective molecular point of care diagnostic tools to provide better healthcare to patients and better agility to our healthcare system. And what about going one step further by extending the limits of molecular diagnostics to the nano-scale?
The market needs a rapid and definitive answer at entry level. Needs a diagnostic that is capable of screen directly and simply hundreds of samples with low infrastructure and low-grade people, that can rely on existing peripheral infrastructure like peripheral hospital and microscopy centres.
We have developed the nano-technology-based solution NANO4. NANO4 is a fast and user-friendly nano-based diagnostic technology suitable for use at the Point of Need. NANO4 represents a highly specific and sensitive nanotechnology for in vitro molecular diagnostics. It uses gold nano-probes to recognize the complementary DNA/RNA strand and yield a colour output that allows for quick decision making.
Molecular diagnosis is a multi-million Euro market and making use of our SME Instrument Phase 1 Feasibility Study, we defined our go-to-market roadmap for our first disruptive products: NANO4 TB for Tuberculosis, and NANO4 CML for Chronic Myeloid Leukaemia, including industrial scale-up and CE mark.
We have already established partnerships with distributors in Europe and Brazil, and our technology has been referenced by FIND as a promising new solution for TB diagnosis. We have also established a connection with the World Health Organization, in order to obtain an endorsement as soon as we receive the CE mark.
NANO4 was founded in end 2015, and we have raised €200.000 from Business Angels and have already begun our operations to take our products to the market, expecting a Series A at the end of 2018.
With the successful conclusion of this project, NANO4 will become one of the few companies in Europe to possess nanotechnology capacities at industrial scale, focused on the life sciences sector.
Champ scientifique
- engineering and technologymaterials engineeringcolors
- engineering and technologynanotechnology
- medical and health sciencesclinical medicinepneumologytuberculosis
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
- medical and health sciencesclinical medicineoncologyleukemia
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
2710-142 Sintra
Portugal
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.